Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis

Reuters

Jul 28, 2025

<a href="https://laohu8.com/S/ENLV">Enlivex Therapeutics Ltd.</a> Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra™ for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra™ injections, with evaluations set for three, six, and twelve months post-treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501144-en) on July 28, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2554477114"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554477114\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554477114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554477114","market":"nz","top_or_hot":-1,"title":"Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a> Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. (Nasdaq: ENLV) has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra™ for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra™ injections, with evaluations set for three, six, and twelve months post-treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501144-en) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENLV\">Enlivex Therapeutics Ltd.</a> Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enlivex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. (Nasdaq: ENLV) has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra™ for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra™ injections, with evaluations set for three, six, and twelve months post-treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501144-en) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLsnbZn:1","article_id":"2554477114","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554477114","pubTimestamp":1753705816,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra for Knee Osteoarthritis. Enlivex Therapeutics Ltd.  has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra injections, with evaluations set for three, six, and twelve months post-treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","ENLV":"Enlivex Therapeutics Ltd.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Enlivex Therapeutics Ltd.确认将于2025年8月18日发布Allocetra II期顶线数据™用于膝骨关节炎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ENLV":0.9},"content_text":"Enlivex Therapeutics Ltd. Confirms August 18, 2025, for Release of Phase II Topline Data on Allocetra™ for Knee Osteoarthritis\n    \n\n        Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has reaffirmed August 18, 2025, as the target date for the announcement of topline data from its Phase II clinical trial of Allocetra™ for patients with moderate to severe knee osteoarthritis. The trial, which has completed its patient follow-ups, aims to assess key endpoints such as safety and changes in knee pain and function. The data from this randomized, controlled, blinded study are currently under analysis and audit. Results are expected to provide insights into the efficacy and safety of Allocetra™ injections, with evaluations set for three, six, and twelve months post-treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9501144-en) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}